Bioretec Ltd Press release 22 November 2024 at 9:30 a.m.EET

TAMPERE, Finland, Nov. 22, 2024 — Bioretec Ltd, a leader in biodegradable orthopedic implants, is expanding its RemeOs™ Trauma Products commercialization in the U.S. Building on its logistics agreement with GlobalMed Logistix, Bioretec has partnered with Tri-State Biologics (TSB), a New Jersey-based medical and surgical product distributor, for sales and distribution. TSB, known for its innovative approach to medical device distribution, will serve hospitals in Greater New York City, Philadelphia, New Jersey, Connecticut, and Massachusetts, covering a significant U.S. population center.

Bioretec’s next step in RemeOs™ Trauma Screw commercialization involves establishing further local sales and distribution agreements for U.S. civilian hospitals, while Spartan Medical continues to serve military and veteran hospitals.

“We’re pleased to announce this agreement with an innovative U.S. medical product distribution partner. The initial U.S. launch of RemeOs™ Trauma Screws showed excellent patient outcomes, with many successful surgeries and post-operative recoveries. This success sets the stage for the next phase of RemeOs™ commercialization and will drive demand among surgeons,” stated Alan Donze, Bioretec Ltd CEO.

Further enquiries
Alan Donze, CEO, tel. +358 40 663 5011
Johanna Salko, CFO, tel. +358 40 754 8172

Bioretec in brief

Bioretec is a global Finnish medical device company specializing in biodegradable orthopedic implants. The company has developed unique expertise in the biological interface of active implants to enhance bone growth and speed fracture healing. Bioretec products are used in approximately 40 countries worldwide.

Bioretec is developing the RemeOs™ product line using a magnesium alloy and hybrid composite, creating a new generation of strong, biodegradable materials for improved surgical results. RemeOs™ implants are absorbed and replaced by bone, eliminating the need for removal surgery and facilitating fracture healing. This approach has the potential to replace titanium implants and help clinics meet Value-Based Healthcare goals by providing better value for patients through efficient care. The first RemeOs™ product received U.S. market authorization in March 2023, and the CE mark approval process is underway in Europe. Bioretec is poised to enter the over USD 9 billion global orthopedic trauma and spine market and transform surgical bone fracture treatment.

Better healing – Better life. 

This information was brought to you by Cision .

 

“`